The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value?

Liver International

Volumn 33, Issue 2, 2013, Pages 172-179

  Dolman, Grace E ^a   Nieboer, Daan ^b   Steyerberg, Ewout W ^b   Harris, Scott ^c   Ferguson, Amanda ^a   Zaitoun, Abed M ^a   Ryder, Stephen D ^a   James, Martin W ^a   Aithal, Guruprasad P ^a   Guha, Indra Neil ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Biomarkers; Cirrhosis; Diagnostic tests; Fibrosis; Liver

Indexed keywords

ADULT; ALGORITHM; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; DISEASE CLASSIFICATION; ELASTOGRAPHY; FEMALE; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; RETROSPECTIVE STUDY; TRANSIENT ELASTOGRAPHY;

AREA UNDER CURVE; CLINICAL COMPETENCE; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC TESTS, ROUTINE; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER CIRRHOSIS; RETROSPECTIVE STUDIES;

EID: 84872145094     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12017     Document Type: Article

References (31)

1. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.
2. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int 2011; 5: 625-34.
3. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.
4. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006; 55: 1650-60.
5. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-51.
6. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-96.
7. Naveau S, Gaude G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105.
8. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48: 1549-57.
9. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72. discussion 207-112.
10. Steyerberg EW, Pencina MJ, Lingsma HF, et al. Assessing the incremental value of diagnostic and prognostic markers: a review and illustration. Eur J Clin Invest 2011; 42: 216-28.
11. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010; 21: 128-38.
12. Lucidarme D, Foucher J, Le Bail B, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1083-9.
13. McCorry RB, Palaniyappan N, Chivinge A, et al. Development and evaluation of a nurse-led transient elastography service for the staging of hepatic fibrosis in patients with suspected chronic liver disease. QJM 2012; 105: 749-54.
14. Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
15. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
17. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med 2003; 29: 1043-51.
18. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9.
19. Roulot D, Costes JL, Buyck JF, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60: 977-84.
20. Moessner BK, Jorgensen TR, Skamling M, et al. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 2011; 106: 970-6.
21. Kaul V, Friedenberg FK, Braitman LE, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002; 97: 2623-8.
22. Niederau C, Lange S, Fruhauf M, Thiel A. Cutaneous signs of liver disease: value for prognosis of severe fibrosis and cirrhosis. Liver Int 2008; 28: 659-66.
23. Udell JA, Wang CS, Tinmouth J, et al. Does this patient with liver disease have cirrhosis? JAMA 2012; 307: 832-42.
24. Romagnuolo J, Jhangri GS, Jewell LD, Bain VG. Predicting the liver histology in chronic hepatitis C: how good is the clinician? Am J Gastroenterol 2001; 96: 3165-74.
25. Gaia S, Carenzi S, Barilli AL, et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54: 64-71.
26. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
27. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010; 51: 828-35.
28. Klibansky DA, Mehta SH, Curry M, et al. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat 2012; 19: e184-93.
29. Fontana RJ, Dienstag JL, Bonkovsky HL, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010; 59: 1401-9.
30. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9, 1979 e1971-1973.
31. Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012; 56: 198-208.